|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.38 | 89.41 | 104.18 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
364.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 8.22 | 9.89 | 4.56 | 2.34 | 2.82 | CEPS(Rs) | 10.52 | 11.84 | 6.24 | 3.77 | 3.42 | DPS(Rs) | 0.10 | 0.10 | 0.10 | 0.05 | 0.05 | Book NAV/Share(Rs) | 35.88 | 27.76 | 17.89 | 13.34 | 9.68 | Tax Rate(%) | 25.31 | 24.44 | 23.36 | 24.69 | 37.93 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 16.81 | 17.45 | 16.18 | 13.31 | 12.76 | EBIT Margin(%) | 14.35 | 15.59 | 13.75 | 11.25 | 12.63 | Pre Tax Margin(%) | 13.33 | 14.96 | 11.13 | 7.70 | 9.81 | PAT Margin (%) | 9.95 | 11.30 | 8.53 | 5.80 | 6.09 | Cash Profit Margin (%) | 12.74 | 13.53 | 11.67 | 9.34 | 7.38 | Performance Ratios | | | | | | ROA(%) | 11.54 | 20.37 | 10.71 | 6.33 | 8.04 | ROE(%) | 25.84 | 43.31 | 29.22 | 22.17 | 33.89 | ROCE(%) | 23.23 | 47.29 | 30.05 | 21.01 | 29.65 | Asset Turnover(x) | 1.16 | 1.80 | 1.26 | 1.09 | 1.32 | Sales/Fixed Asset(x) | 3.76 | 5.17 | 3.94 | 5.14 | 10.57 | Working Capital/Sales(x) | 4.55 | 6.31 | 5.35 | 11.67 | 7.81 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.27 | 0.19 | 0.25 | 0.19 | 0.09 | Receivable days | 81.36 | 59.40 | 81.43 | 97.98 | 93.16 | Inventory Days | 68.14 | 45.18 | 76.30 | 101.05 | 95.44 | Payable days | 167.52 | 124.89 | 184.25 | 227.30 | 173.92 | Valuation Parameters | | | | | | PER(x) | 22.70 | 25.18 | 25.05 | 20.15 | 26.98 | PCE(x) | 17.74 | 21.02 | 18.30 | 12.51 | 22.26 | Price/Book(x) | 5.20 | 8.97 | 6.39 | 3.53 | 7.86 | Yield(%) | 0.05 | 0.04 | 0.09 | 0.11 | 0.07 | EV/Net Sales(x) | 3.00 | 3.14 | 2.36 | 1.47 | 1.94 | EV/Core EBITDA(x) | 15.12 | 16.20 | 13.12 | 9.63 | 13.60 | EV/EBIT(x) | 18.05 | 18.51 | 16.12 | 12.66 | 14.99 | EV/CE(x) | 3.15 | 7.41 | 5.03 | 2.27 | 3.94 | M Cap / Sales | 2.62 | 3.10 | 2.27 | 1.21 | 1.69 | Growth Ratio | | | | | | Net Sales Growth(%) | -11.36 | 59.76 | 28.74 | 8.00 | 14.79 | Core EBITDA Growth(%) | -9.20 | 72.42 | 51.37 | 15.45 | 20.44 | EBIT Growth(%) | -13.06 | 85.30 | 62.00 | -3.23 | 17.19 | PAT Growth(%) | -16.84 | 116.68 | 94.96 | 3.41 | 33.17 | EPS Growth(%) | -16.83 | 116.67 | 94.96 | -16.98 | 33.17 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.90 | 0.23 | 0.32 | 0.90 | 1.30 | Current Ratio(x) | 1.61 | 1.72 | 1.51 | 1.14 | 1.21 | Quick Ratio(x) | 0.97 | 1.10 | 1.01 | 0.63 | 0.78 | Interest Cover(x) | 13.98 | 24.64 | 5.23 | 3.17 | 4.48 | Total Debt/Mcap(x) | 0.17 | 0.03 | 0.06 | 0.32 | 0.17 |
|
|
|
|
|
|